Research Solutions (RSSS) 10-Q 11 Feb 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2020	Feb. 05, 2021
Document And Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	Research Solutions, Inc.
Entity Central Index Key	0001386301
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Trading Symbol	RSSS
Entity Common Stock, Shares Outstanding		26,277,679
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common stock, $0.001 par value
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 10,163,504	$ 9,311,556
Accounts receivable, net of allowance of $47,830 and $88,485, respectively	4,227,603	4,449,260
Prepaid expenses and other current assets	297,280	241,747
Prepaid royalties	673,864	720,367
Total current assets	15,362,251	14,722,930
Other assets:
Property and equipment, net of accumulated depreciation of $819,263 and $804,999, respectively	11,677	11,276
Deposits and other assets	6,280	6,155
Right of use asset, net of accumulated amortization of $452,577 and $390,691, respectively	10,445	72,331
Total assets	15,390,653	14,812,692
Current liabilities:
Accounts payable and accrued expenses	5,799,152	6,349,845
Deferred revenue	4,385,507	3,524,507
Lease liability, current portion	11,444	79,326
Total current liabilities	10,196,103	9,953,678
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 26,266,008 and 26,032,263 shares issued and outstanding, respectively	26,266	26,032
Additional paid-in capital	26,709,401	26,134,819
Accumulated deficit	(21,422,760)	(21,176,799)
Accumulated other comprehensive loss	(118,357)	(125,038)
Total stockholders' equity	5,194,550	4,859,014
Total liabilities and stockholders' equity	$ 15,390,653	$ 14,812,692

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Jun. 30, 2020
Allowance for Doubtful Accounts Receivable, Current	$ 47,830	$ 88,485
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 819,263	$ 804,999
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	26,266,008	26,032,263
Common Stock, Shares, Outstanding	26,266,008	26,032,263
Use Rights [Member]
Finite-Lived Intangible Assets, Accumulated Amortization	$ 452,577	$ 390,691

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 7,449,735	$ 7,530,438	$ 15,198,160	$ 15,125,551
Cost of revenue:
Total cost of revenue	5,058,153	5,256,638	10,357,002	10,535,216
Gross profit	2,391,582	2,273,800	4,841,158	4,590,335
Operating expenses:
Selling, general and administrative	2,649,548	2,976,107	5,078,486	5,411,787
Depreciation and amortization	3,039	6,840	6,762	14,398
Total operating expenses	2,652,587	2,982,947	5,085,248	5,426,185
Loss from operations	(261,005)	(709,147)	(244,090)	(835,850)
Other income	399	26,527	634	52,076
Loss from operations before provision for income taxes	(260,606)	(682,620)	(243,456)	(783,774)
Provision for income taxes	0	(806)	(2,505)	(7,300)
Loss from continuing operations	(260,606)	(683,426)	(245,961)	(791,074)
Gain from sale of discontinued operations	0	91,254	0	117,445
Net loss	(260,606)	(592,172)	(245,961)	(673,629)
Other comprehensive income (loss):
Foreign currency translation	5,516	1,543	6,681	(2,025)
Comprehensive loss	$ (255,090)	$ (590,629)	$ (239,280)	$ (675,654)
Loss per common share:
Loss per share from continuing operations, basic and diluted	$ (0.01)	$ (0.03)	$ (0.01)	$ (0.03)
Income per share from discontinued operations, basic and diluted	0	0	0	0
Net loss per share, basic and diluted	$ (0.01)	$ (0.03)	$ (0.01)	$ (0.03)
Weighted average common shares outstanding, basic and diluted	25,988,117	24,185,966	25,943,509	24,140,616
Platforms [Member]
Revenue:
Total revenue	$ 1,220,535	$ 949,825	$ 2,362,223	$ 1,806,270
Cost of revenue:
Total cost of revenue	217,003	162,508	420,955	312,978
Transactions [Member]
Revenue:
Total revenue	6,229,200	6,580,613	12,835,937	13,319,281
Cost of revenue:
Total cost of revenue	$ 4,841,150	$ 5,094,130	$ 9,936,047	$ 10,222,238

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Loss	Total
Balance at Jun. 30, 2019	$ 24,376	$ 23,631,481	$ (20,514,557)	$ (109,585)	$ 3,031,715
Balance (in shares) at Jun. 30, 2019	24,375,948
Fair value of vested stock options	$ 0	58,198	0	0	58,198
Fair value of vested restricted common stock	$ 70	84,404	0	0	84,474
Fair value of vested restricted common stock (in shares)	70,000
Repurchase of common stock	$ (28)	(71,847)	0	0	(71,875)
Repurchase of common stock (in shares)	(28,750)
Common stock issued upon exercise of stock options	$ 24	(24)	0	0	0
Common stock issued upon exercise of stock options (in shares)	24,307
Net income (loss) for the period	$ 0	0	(81,457)	0	(81,457)
Foreign currency translation	0	0	0	(3,568)	(3,568)
Balance at Sep. 30, 2019	$ 24,442	23,702,212	(20,596,014)	(113,153)	3,017,487
Balance (in shares) at Sep. 30, 2019	24,441,505
Balance at Jun. 30, 2019	$ 24,376	23,631,481	(20,514,557)	(109,585)	3,031,715
Balance (in shares) at Jun. 30, 2019	24,375,948
Net income (loss) for the period					(673,629)
Foreign currency translation					(2,025)
Balance at Dec. 31, 2019	$ 24,476	24,098,311	(21,188,186)	(111,610)	2,822,991
Balance (in shares) at Dec. 31, 2019	24,475,556
Balance at Jun. 30, 2019	$ 24,376	23,631,481	(20,514,557)	(109,585)	3,031,715
Balance (in shares) at Jun. 30, 2019	24,375,948
Balance at Jun. 30, 2020	$ 26,032	26,134,819	(21,176,799)	(125,038)	4,859,014
Balance (in shares) at Jun. 30, 2020	26,032,263
Balance at Sep. 30, 2019	$ 24,442	23,702,212	(20,596,014)	(113,153)	3,017,487
Balance (in shares) at Sep. 30, 2019	24,441,505
Fair value of vested stock options	$ 0	437,992	0	0	437,992
Fair value of vested restricted common stock	$ 14	85,626	0	0	85,640
Fair value of vested restricted common stock (in shares)	13,978
Repurchase of common stock	$ (42)	(127,457)	0	0	(127,499)
Repurchase of common stock (in shares)	(42,500)
Common stock issued upon exercise of stock options	$ 62	(62)	0	0	0
Common stock issued upon exercise of stock options (in shares)	62,573
Net income (loss) for the period	$ 0	0	(592,172)	0	(592,172)
Foreign currency translation	0	0	0	1,543	1,543
Balance at Dec. 31, 2019	$ 24,476	24,098,311	(21,188,186)	(111,610)	2,822,991
Balance (in shares) at Dec. 31, 2019	24,475,556
Balance at Jun. 30, 2020	$ 26,032	26,134,819	(21,176,799)	(125,038)	4,859,014
Balance (in shares) at Jun. 30, 2020	26,032,263
Fair value of vested stock options	$ 0	77,627	0	0	77,627
Fair value of vested restricted common stock	$ 120	93,044	0	0	93,164
Fair value of vested restricted common stock (in shares)	120,000
Repurchase of common stock	$ (25)	(58,370)	0	0	(58,395)
Repurchase of common stock (in shares)	(25,500)
Common stock issued upon exercise of stock options	$ 64	14,036	0	0	14,100
Common stock issued upon exercise of stock options (in shares)	63,950
Net income (loss) for the period	$ 0	0	14,645	0	14,645
Foreign currency translation	0	0	0	1,165	1,165
Balance at Sep. 30, 2020	$ 26,191	26,261,156	(21,162,154)	(123,873)	5,001,320
Balance (in shares) at Sep. 30, 2020	26,190,713
Balance at Jun. 30, 2020	$ 26,032	26,134,819	(21,176,799)	(125,038)	4,859,014
Balance (in shares) at Jun. 30, 2020	26,032,263
Fair value of vested stock options					$ 419,785
Repurchase of common stock (in shares)	(56,667)
Common stock issued upon exercise of stock options (in shares)					182,853
Net income (loss) for the period					$ (245,961)
Foreign currency translation					6,681
Balance at Dec. 31, 2020	$ 26,266	26,709,401	(21,422,760)	(118,357)	5,194,550
Balance (in shares) at Dec. 31, 2020	26,266,008
Balance at Sep. 30, 2020	$ 26,191	26,261,156	(21,162,154)	(123,873)	5,001,320
Balance (in shares) at Sep. 30, 2020	26,190,713
Fair value of vested stock options	$ 0	342,158	0	0	342,158
Fair value of vested restricted common stock	$ 23	93,767	0	0	93,790
Fair value of vested restricted common stock (in shares)	23,474
Repurchase of common stock	$ (31)	(68,848)	0	0	(68,879)
Repurchase of common stock (in shares)	(31,167)
Common stock issued upon exercise of stock options	$ 18	(18)	0	0	0
Common stock issued upon exercise of stock options (in shares)	17,988
Common stock issued upon exercise of warrants	$ 65	81,186	0	0	81,251
Common stock issued upon exercise of warrants (in shares)	65,000
Net income (loss) for the period	$ 0	0	(260,606)	0	(260,606)
Foreign currency translation	0	0	0	5,516	5,516
Balance at Dec. 31, 2020	$ 26,266	$ 26,709,401	$ (21,422,760)	$ (118,357)	$ 5,194,550
Balance (in shares) at Dec. 31, 2020	26,266,008

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flow from operating activities:
Net loss	$ (245,961)	$ (673,629)
Adjustment to reconcile net loss to net cash provided by operating activities:
Gain from sale of discontinued operations	0	(117,445)
Depreciation and amortization	6,762	14,398
Amortization of lease right	61,886	59,332
Fair value of vested stock options	419,785	496,190
Fair value of vested restricted common stock	186,954	170,114
Changes in operating assets and liabilities:
Accounts receivable	221,657	342,389
Prepaid expenses and other current assets	(55,533)	125,262
Prepaid royalties	46,503	(301,110)
Deposits and other assets	0	8,094
Accounts payable and accrued expenses	(550,693)	993,845
Deferred revenue	861,000	563,209
Lease liability	(67,882)	(62,998)
Net cash provided by operating activities	884,478	1,617,651
Cash flow from investing activities:
Purchase of property and equipment	(6,134)	0
Net cash used in investing activities	(6,134)	0
Cash flow from financing activities:
Proceeds from the exercise of stock options	14,100	0
Proceeds from the exercise of warrants	81,251	0
Common stock repurchase and retirement	(127,274)	(199,374)
Net cash used in financing activities	(31,923)	(199,374)
Effect of exchange rate changes	5,527	(2,239)
Net increase in cash and cash equivalents	851,948	1,416,038
Cash and cash equivalents, beginning of period	9,311,556	5,353,090
Cash and cash equivalents, end of period	10,163,504	6,769,128
Supplemental disclosures of cash flow information:
Cash paid for income taxes	$ 2,505	$ 7,300

Organization, Nature of Busines

Organization, Nature of Business and Basis of Presentation	6 Months Ended
	Dec. 31, 2020
Organization, Nature of Business and Basis of Presentation
Organization, Nature of Business and Basis of Presentation	Note 1. Organization, Nature of Business and Basis of Presentation Organization Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with two wholly owned subsidiaries: Reprints Desk, Inc., a Delaware corporation and Reprints Desk Latin America S. de R.L. de C.V, an entity organized under the laws of Mexico. Nature of Business We provide two service offerings to our customers: annual licenses that allow customers to access and utilize certain premium features of our cloud based software-as-a-service (“SaaS”) research intelligence platform (“Platforms”) and the transactional sale of published scientific, technical, and medical (“STM”) content managed, sourced and delivered through the Platform (“Transactions”). Platforms and Transactions are packaged as a single solution that enable life science and other research intensive organizations to speed up research and development activities with faster, single sourced access and management of content and data used throughout the intellectual property development lifecycle. Platforms Our cloud-based SaaS research intelligence platform consists of proprietary software and Internet-based interfaces sold to customers for an annual subscription fee. Legacy functionality allows customers to initiate orders, route orders for the lowest cost acquisition, manage transactions, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. Customers can also enhance the information resources they already own or license and collaborate around bibliographic information. Additional functionality has recently been added to our Platform in the form of interactive app-like gadgets. An alternative to manual data filtering, identification and extraction, gadgets are designed to gather, augment, and extract data across a variety of formats, including bibliographic citations, tables of contents, RSS feeds, PDF files, XML feeds, and web content. We are rapidly developing new gadgets in order to build an ecosystem of gadgets. Together, these gadgets will provide researchers with an “all in one” toolkit, delivering efficiencies in core research workflows and knowledge creation processes. Our Platform is deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platform through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platform can also be configured to satisfy a customer’s individual preferences. We leverage our Platform’s efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage. Transactions Our Platform provides our customers with a single source to the universe of published STM content that includes over 70 million existing STM articles and over one million newly published STM articles each year. STM content is sold to our customers on a transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users. Our Platform allows customers to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of minutes. Principles of Consolidation The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10‑K for the fiscal year ended June 30, 2020 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2020 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets. Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required. Cash denominated in Euros with a US Dollar equivalent of $93,925 and $134,175 at December 31, 2020 and June 30, 2020, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe. The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2020 and 2019. The following table summarizes accounts receivable concentrations: As of December 31, June 30, 2020 2020 Customer A % * * Less than 10% The following table summarizes vendor concentrations: Three Months Ended Six Months Ended December 31, December 31, 2020 2019 2020 2019 Vendor A 18 % 22 % 18 % 21 % Vendor B 13 % 12 % 13 % 12 % Vendor C * 11 % * * * Less than 10% Revenue Recognition The Company accounts for revenue in accordance ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. The Company adopted the guidance of ASC 606 on July 1, 2018. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”). The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. Platforms We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met. Deferred Revenue Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer. Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets. Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers. Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered. Foreign Currency The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to gain of $17,469 and $5,456 for the three months ended December 31, 2020 and 2019, respectively and a gain of $41,718 and a loss of $6,667 for the six months ended December 31, 2020 and 2019, respectively. Cash denominated in Euros with a US Dollar equivalent of $93,925 and $134,175 at December 31, 2020 and June 30, 2020, respectively, was held in accounts at financial institutions located in Europe. The following table summarizes the exchange rates used: Six Months Ended Year Ended December 31, June 30, 2020 2019 2020 2019 Period end Euro : US Dollar exchange rate 1.23 1.12 1.12 1.14 Average period Euro : US Dollar exchange rate 1.17 1.11 1.14 1.14 Period end Mexican Peso : US Dollar exchange rate 0.05 0.05 0.04 0.05 Average period Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05 Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At December 31, 2020 potentially dilutive securities include options to acquire 3,564,018 shares of common stock, warrants to acquire 320,000 shares of common stock and unvested restricted common stock of 250,553. At December 31, 2019 potentially dilutive securities include options to acquire 3,416,580 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 254,283. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period. Basic and diluted net loss per common share is the same for the three and six months ended December 31, 2020 and 2019 because all stock options, warrants, and unvested restricted common stock are anti-dilutive. Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Line of Credit

Line of Credit	6 Months Ended
	Dec. 31, 2020
Line of Credit
Line of Credit	Note 3. Line of Credit The Company entered into a Loan and Security Agreement with Silicon Valley Bank (“SVB”) on July 23, 2010, which, as amended, provides for a revolving line of credit for the lesser of $2,500,000, or 80% of eligible accounts receivable. The line of credit matures on February 14, 2022, and is subject to certain financial and performance covenants with which we were in compliance as of December 31, 2020. Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt. The line of credit bears interest at an annual rate equal to the greater of 1% above the prime rate and 5.5%. The interest rate on the line of credit was 5.5% as of December 31, 2020. The line of credit is secured by the Company’s consolidated assets. There were no outstanding borrowings under the line as of December 31, 2020 and June 30, 2020, respectively. As of December 31, 2020, there was approximately $1,722,000 of available credit.

Lease Obligations

Lease Obligations	6 Months Ended
	Dec. 31, 2020
Lease Obligations
Lease Obligations	Note 4. Lease Obligations On December 30, 2016, the Company entered into a 48 month non-cancellable lease for its office facilities that will require monthly payments ranging from $10,350 to $11,475 through January 2021. In accounting for the lease, the Company adopted ASU 2016‑02, Leases which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease assets and liability at the inception of the lease was $463,000 using a discount rate of 3.75%. During the six months ended December 31, 2020, the Company made payments of $67,882 towards the lease liability. As of December 31, 2020 and June 30, 2020, lease liability amounted to $11,444 and $79,326, respectively. ASU 2016‑02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense, including real estate taxes, for the six months ended December 31, 2020 and 2019 was $25,986 and $83,324, respectively. The right of use asset at June 30, 2020 was $72,331. During the six months ended December 31, 2020, the Company reflected amortization of right of use asset of $61,886 related to this lease, resulting in a net asset balance of $10,445 as of December 31, 2020. On October 8, 2019, the Company entered into an agreement to sublease its office facilities from November 1, 2019 through January 31, 2021, the end of the lease term, for $8,094 per month with one month of abated rent. The Company recorded rent income of $48,564 during the six months ended December 31, 2020. This amount is reflected as an offset to rent expense that is included in general and administrative expenses in the accompanying statements of operations.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Dec. 31, 2020
Stockholders' Equity
Stockholders' Equity	Note 5. Stockholders’ Equity Stock Options In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. On November 17, 2020, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 2,374,513 to 3,374,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the 2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of December 31, 2020, there were 1,059,664 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan. The majority of awards issued under the Plan vest immediately or over three years, with a one year cliff vesting period, and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period. The following table summarizes vested and unvested stock option activity: All Options Vested Options Unvested Options Weighted Weighted Weighted Average Average Average Exercise Exercise Exercise Shares Price Shares Price Shares Price Outstanding at June 30, 2020 3,327,580 $ 1.56 3,081,745 $ 1.50 245,835 $ 2.34 Granted 439,708 2.26 250,000 2.13 189,708 2.42 Options vesting — — 97,165 2.22 (97,165) 2.22 Exercised (182,853) 1.38 (182,853) 1.38 — — Forfeited/Cancelled (20,417) 1.92 — — (20,417) 1.92 Outstanding at December 31, 2020 3,564,018 $ 1.65 3,246,057 $ 1.58 317,961 $ 2.44 The weighted average remaining contractual life of all options outstanding as of December 31, 2020 was 5.92 years. The remaining contractual life for options vested and exercisable at December 31, 2020 was 5.72 years. Furthermore, the aggregate intrinsic value of options outstanding as of December 31, 2020 was $2,697,071, and the aggregate intrinsic value of options vested and exercisable at December 31, 2020 was $2,687,396, in each case based on the fair value of the Company’s common stock on December 31, 2020. During the six months ended December 31, 2020, the Company granted 439,708 options to employees with a fair value of $522,954 which amount will be amortized over the vesting period. The total fair value of options that vested during the six months ended December 31, 2020 was $419,785 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of December 31, 2020, the amount of unvested compensation related to stock options was $392,185 which will be recorded as an expense in future periods as the options vest. During the six months ended December 31, 2020, the Company issued 81,938 net shares of common stock upon the exercise of options underlying 182,853 shares of common stock, resulting in net cash proceeds of $14,000. The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the six months ended December 31, 2020 and 2019. Six Months Ended December 31, 2020 2019 Expected dividend yield 0 % 0 % Risk-free interest rate 0.37% - 0.51 % 1.61% - 1.69 % Expected life (in years) 5 - 6 5 - 6 Expected volatility 60 - 63 % 64 % Additional information regarding stock options outstanding and exercisable as of December 31, 2020 is as follows: Remaining Option Options Contractual Options Exercise Price Outstanding Life (in years) Exercisable $ 0.59 8,150 8,150 0.60 5,000 5,000 0.65 6,150 6,150 0.70 225,000 225,000 0.77 49,500 49,500 0.80 16,000 16,000 0.90 25,667 25,667 0.97 6,000 6,000 1.00 28,249 28,249 1.02 2,000 2,000 1.05 400,529 400,529 1.07 33,898 33,898 1.09 121,250 121,250 1.10 105,000 105,000 1.15 193,400 193,400 1.20 349,000 349,000 1.25 32,000 32,000 1.30 243,000 243,000 1.50 195,000 195,000 1.59 25,000 22,915 1.80 94,050 94,050 1.85 17,800 17,800 1.95 200,000 166,666 2.13 266,708 250,000 2.40 398,667 359,833 2.45 173,000 — 2.49 50,000 25,000 2.50 20,000 11,667 2.99 8,000 — 3.13 258,000 253,333 3.50 8,000 — Total 3,564,018 3,246,057 Warrants The following table summarizes warrant activity: Weighted Average Number of Exercise Warrants Price Outstanding, June 30, 2020 385,000 $ 1.24 Granted — — Exercised (65,000) 1.25 Expired/Cancelled — — Outstanding, December 31, 2020 320,000 $ 1.24 Exercisable, June 30, 2020 385,000 $ 1.24 Exercisable, December 31, 2020 320,000 $ 1.24 The intrinsic value for all warrants outstanding as of December 31, 2020 was $348,600, based on the fair value of the Company’s common stock on December 31, 2020. During the six months ended December 31, 2020, certain holders of warrants to purchase shares of the Company's common stock at a per share exercise price of $1.25 exercised those warrants to purchase 65,000 shares of common stock, generating gross proceeds to the Company of $81,251. Additional information regarding warrants outstanding and exercisable as of December 31, 2020 is as follows: Remaining Warrant Warrants Contractual Warrants Exercise Price Outstanding Life (in years) Exercisable $ 1.19 50,000 50,000 1.25 270,000 270,000 Total 320,000 320,000 Restricted Common Stock Prior to July 1, 2020, the Company issued 2,277,366 shares of restricted common stock to employees valued at $2,709,318, of which 1,871,187 shares have vested, 214,324 shares with fair value of $188,203 have been forfeited, and $1,785,857 has been recognized as an expense. The balance of the non-vested shares of restricted common stock was 191,855 at June 30, 2020. During the six months ended December 31, 2020, the Company issued an additional 143,474 shares of restricted stock to employees. These shares vest over a three year period, with a one year cliff vesting period, and remain subject to forfeiture if vesting conditions are not met. The aggregate fair value of the stock awards was $344,000 based on the market price of our common stock price of $2.40 per share on the date of grant, which will be amortized over the three-year vesting period. The total fair value of restricted common stock vesting during the three months ended December 31, 2020 was $186,954 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of December 31, 2020, the amount of unvested compensation related to issuances of restricted common stock was $551,343, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income (loss) per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. The following table summarizes restricted common stock activity: Weighted Average Number of Grant Date Shares Fair Value Fair Value Non-vested, June 30, 2020 191,855 $ 394,297 $ 2.51 Granted 143,474 344,000 2.40 Vested (84,776) (186,954) 2.29 Forfeited — — — Non-vested, December 31, 2020 250,553 $ 551,343 $ 2.52 Common Stock Repurchase and Retirement Effective as of February 11, 2020, the Compensation Committee of our Board of Directors authorized the repurchase, during calendar year 2020 on the last day of each trading window and otherwise in accordance with our insider trading policies, of up to $400,000 of outstanding common stock (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards. The actual number of shares repurchased will be determined by applicable employees in their discretion, and will depend on their evaluation of market conditions and other factors. During the six months ended December 31, 2020, the Company repurchased 56,667 shares of our common stock from employees at an average market price of approximately $2.25 per share for an aggregate amount of $127,274. As of December 31, 2020, the 2020 plan has expired. The shares of common stock were surrendered by employees to cover tax withholding obligations with respect to the vesting of restricted stock. Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value.

Contingencies

Contingencies	6 Months Ended
	Dec. 31, 2020
Contingencies
Contingencies	Note 6. Contingencies COVID-19 The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. To date, we have not experienced any significant changes in our business that would have a significant negative impact on our consolidated statements of operations or cash flows. The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2020
Subsequent Events
Subsequent Events	Note 7. Subsequent Events On January 14, 2021, the Company issued 11,671 net shares of common stock upon the cashless exercise of stock options underlying 26,667 shares of common stock.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required. Cash denominated in Euros with a US Dollar equivalent of $93,925 and $134,175 at December 31, 2020 and June 30, 2020, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe. The Company has no customers that represent 10% of revenue or more for the three and six months ended December 31, 2020 and 2019. The following table summarizes accounts receivable concentrations: As of December 31, June 30, 2020 2020 Customer A % * * Less than 10% The following table summarizes vendor concentrations: Three Months Ended Six Months Ended December 31, December 31, 2020 2019 2020 2019 Vendor A 18 % 22 % 18 % 21 % Vendor B 13 % 12 % 13 % 12 % Vendor C * 11 % * * * Less than 10%
Revenue Recognition	Revenue Recognition The Company accounts for revenue in accordance ASU 2014‑09, Revenue from Contracts with Customers (Topic 606), ("ASC 606"). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. The Company adopted the guidance of ASC 606 on July 1, 2018. Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual licenses that allow customers to access and utilize certain premium features of our cloud based SaaS research intelligence platform (“Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”). The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. Platforms We charge a subscription fee that allows customers to access and utilize certain premium features of our Platform. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue. Transactions We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.
Deferred Revenue	Deferred Revenue Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer. Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets.
Cost of Revenue	Cost of Revenue Platforms Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers. Transactions Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.
Foreign Currency	Foreign Currency The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities. Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to gain of $17,469 and $5,456 for the three months ended December 31, 2020 and 2019, respectively and a gain of $41,718 and a loss of $6,667 for the six months ended December 31, 2020 and 2019, respectively. Cash denominated in Euros with a US Dollar equivalent of $93,925 and $134,175 at December 31, 2020 and June 30, 2020, respectively, was held in accounts at financial institutions located in Europe. The following table summarizes the exchange rates used: Six Months Ended Year Ended December 31, June 30, 2020 2019 2020 2019 Period end Euro : US Dollar exchange rate 1.23 1.12 1.12 1.14 Average period Euro : US Dollar exchange rate 1.17 1.11 1.14 1.14 Period end Mexican Peso : US Dollar exchange rate 0.05 0.05 0.04 0.05 Average period Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. At December 31, 2020 potentially dilutive securities include options to acquire 3,564,018 shares of common stock, warrants to acquire 320,000 shares of common stock and unvested restricted common stock of 250,553. At December 31, 2019 potentially dilutive securities include options to acquire 3,416,580 shares of common stock, warrants to acquire 1,885,000 shares of common stock and unvested restricted common stock of 254,283. The dilutive effect of potentially dilutive securities is reflected in diluted net income per share if the exercise prices were lower than the average fair market value of common shares during the reporting period. Basic and diluted net loss per common share is the same for the three and six months ended December 31, 2020 and 2019 because all stock options, warrants, and unvested restricted common stock are anti-dilutive.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning January 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Dec. 31, 2020
Summary of Significant Accounting Policies
Schedule of accounts receivable concentrations	As of December 31, June 30, 2020 2020 Customer A % * * Less than 10%
Schedule of Concentration of Risk	Three Months Ended Six Months Ended December 31, December 31, 2020 2019 2020 2019 Vendor A 18 % 22 % 18 % 21 % Vendor B 13 % 12 % 13 % 12 % Vendor C * 11 % * * * Less than 10%
Schedule Of Foreign Currency Exchange Rate	Six Months Ended Year Ended December 31, June 30, 2020 2019 2020 2019 Period end Euro : US Dollar exchange rate 1.23 1.12 1.12 1.14 Average period Euro : US Dollar exchange rate 1.17 1.11 1.14 1.14 Period end Mexican Peso : US Dollar exchange rate 0.05 0.05 0.04 0.05 Average period Mexican Peso : US Dollar exchange rate 0.05 0.05 0.05 0.05

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2020
Stockholders' Equity
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes vested and unvested stock option activity: All Options Vested Options Unvested Options Weighted Weighted Weighted Average Average Average Exercise Exercise Exercise Shares Price Shares Price Shares Price Outstanding at June 30, 2020 3,327,580 $ 1.56 3,081,745 $ 1.50 245,835 $ 2.34 Granted 439,708 2.26 250,000 2.13 189,708 2.42 Options vesting — — 97,165 2.22 (97,165) 2.22 Exercised (182,853) 1.38 (182,853) 1.38 — — Forfeited/Cancelled (20,417) 1.92 — — (20,417) 1.92 Outstanding at December 31, 2020 3,564,018 $ 1.65 3,246,057 $ 1.58 317,961 $ 2.44
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following table presents the assumptions used to estimate the fair values based upon a Black-Scholes option pricing model of the stock options granted during the six months ended December 31, 2020 and 2019. Six Months Ended December 31, 2020 2019 Expected dividend yield 0 % 0 % Risk-free interest rate 0.37% - 0.51 % 1.61% - 1.69 % Expected life (in years) 5 - 6 5 - 6 Expected volatility 60 - 63 % 64 %
Schedule of Share-based Compensation, by Exercise Price Range	Additional information regarding stock options outstanding and exercisable as of December 31, 2020 is as follows: Remaining Option Options Contractual Options Exercise Price Outstanding Life (in years) Exercisable $ 0.59 8,150 8,150 0.60 5,000 5,000 0.65 6,150 6,150 0.70 225,000 225,000 0.77 49,500 49,500 0.80 16,000 16,000 0.90 25,667 25,667 0.97 6,000 6,000 1.00 28,249 28,249 1.02 2,000 2,000 1.05 400,529 400,529 1.07 33,898 33,898 1.09 121,250 121,250 1.10 105,000 105,000 1.15 193,400 193,400 1.20 349,000 349,000 1.25 32,000 32,000 1.30 243,000 243,000 1.50 195,000 195,000 1.59 25,000 22,915 1.80 94,050 94,050 1.85 17,800 17,800 1.95 200,000 166,666 2.13 266,708 250,000 2.40 398,667 359,833 2.45 173,000 — 2.49 50,000 25,000 2.50 20,000 11,667 2.99 8,000 — 3.13 258,000 253,333 3.50 8,000 — Total 3,564,018 3,246,057
Schedule of Other Share-based Compensation, Activity	The following table summarizes warrant activity: Weighted Average Number of Exercise Warrants Price Outstanding, June 30, 2020 385,000 $ 1.24 Granted — — Exercised (65,000) 1.25 Expired/Cancelled — — Outstanding, December 31, 2020 320,000 $ 1.24 Exercisable, June 30, 2020 385,000 $ 1.24 Exercisable, December 31, 2020 320,000 $ 1.24
Schedule of Stockholders' Equity Note, Warrants or Rights	Additional information regarding warrants outstanding and exercisable as of December 31, 2020 is as follows: Remaining Warrant Warrants Contractual Warrants Exercise Price Outstanding Life (in years) Exercisable $ 1.19 50,000 50,000 1.25 270,000 270,000 Total 320,000 320,000
Schedule of Non-vested Restricted Stock Units Activity	The following table summarizes restricted common stock activity: Weighted Average Number of Grant Date Shares Fair Value Fair Value Non-vested, June 30, 2020 191,855 $ 394,297 $ 2.51 Granted 143,474 344,000 2.40 Vested (84,776) (186,954) 2.29 Forfeited — — — Non-vested, December 31, 2020 250,553 $ 551,343 $ 2.52

Organization, Nature of Busin_2

Organization, Nature of Business and Basis of Presentation (Details)	Dec. 31, 2020subsidiaryitem
Organization, Nature of Business and Basis of Presentation
Number Of Subsidiaries | subsidiary	2
Number Of Service Offerings | item	2

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Content costs (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Customer A [Member]
Concentration Risk, Percentage			11.00%
Vendor A [Member]
Concentration Risk, Percentage	18.00%	22.00%	18.00%	21.00%
Vendor B [Member]
Concentration Risk, Percentage	13.00%	12.00%	13.00%	12.00%
Vendor C [Member]
Concentration Risk, Percentage		11.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Exchange rates (Details)	6 Months Ended		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Euro to US Dollar [Member]
Period end exchange rate	1.23	1.12	1.12	1.14
Average period exchange rate	1.17	1.11	1.14	1.14
Mexican Peso to US Dollar [Member]
Period end exchange rate	0.05	0.05	0.04	0.05
Average period exchange rate	0.05	0.05	0.05	0.05

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended
	Dec. 31, 2020USD ($)item	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)itemshares	Dec. 31, 2019USD ($)shares	Jun. 30, 2020USD ($)
Cash, FDIC Insured Amount	$ 250,000		$ 250,000
Foreign Currency Transaction Gain (Loss), before Tax	$ 17,469	$ 5,456	$ 41,718	$ (6,667)
Number Of Revenue Sources | item	2		2
Revenues	$ 7,449,735	$ 7,530,438	$ 15,198,160	$ 15,125,551
Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			250,553	254,283
Sales Revenue, Net [Member]
Concentration Risk, Percentage	10.00%	10.00%	10.00%	10.00%
Europe Financial Institutions [Member]
Deposits	$ 93,925		$ 93,925		$ 134,175
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			3,564,018	3,416,580
Employee Stock Option [Member] | Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares			320,000	1,885,000

Line of Credit (Details)

Line of Credit (Details) - USD ($)	Jul. 23, 2010	Dec. 31, 2020	Jun. 30, 2020
Line of Credit Facility, Interest Rate Description		1% above the prime rate
Line of Credit Facility, Remaining Borrowing Capacity		$ 1,722,000
Debt Instrument, Covenant Description		Financial covenants include maintaining an adjusted quick ratio of unrestricted cash and net accounts receivable, divided by current liabilities plus debt less deferred revenue of at least 1.15 to 1.0, and maintaining tangible net worth of $1,500,000, plus 50% of net income for the fiscal quarter ended from and after December 31, 2017, plus 50% of the dollar value of equity issuances after October 1, 2017 and the principal amount of subordinated debt.
Silicon Valley Bank [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,500,000
Percentage Of Eligible Accounts Receivable On Line Of Credit	80.00%
Line of Credit Facility, Amount Outstanding		$ 0	$ 0
Line of Credit Facility, Interest Rate at Period End		5.50%

Lease Obligations - Additional

Lease Obligations - Additional Information (Details) - USD ($)	Oct. 08, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Dec. 30, 2016
Lessee, Operating Lease, Term of Contract					48 months
Operating Lease Liabilities, Fair Value		$ 463,000
Operating Lease Discount Rate		3.75%
Operating Lease, Payments		$ 67,882
Operating Lease, Liability		11,444		$ 79,326
Operating Leases, Rent Expense		25,986	$ 83,324
Other Assets, Noncurrent		10,445		$ 72,331
Amortization of Leased Asset		61,886	$ 59,332
Sublease Income	$ 8,094
Rental Income, Nonoperating		$ 48,564
Minimum [Member]
Operating Leases, Future Minimum Payments Due					$ 10,350
Maximum [Member]
Operating Leases, Future Minimum Payments Due					$ 11,475

Stockholders' Equity - Vested a

Stockholders' Equity - Vested and unvested stock option (Details)	6 Months Ended
	Dec. 31, 2020$ / sharesshares
Outstanding beginning balance Shares | shares	3,327,580
Granted Shares | shares	439,708
Options vesting Shares | shares	0
Exercised Shares | shares	(182,853)
Forfeited/Cancelled Shares | shares	(20,417)
Outstanding ending balance Shares | shares	3,564,018
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.56
Granted Weighted Average Exercise Price | $ / shares	2.26
Options vesting Weighted Average Exercise Price | $ / shares	0
Exercised Weighted Average Exercise Price | $ / shares	1.38
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	1.92
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.65
Vested Options [Member]
Outstanding beginning balance Shares | shares	3,081,745
Granted Shares | shares	250,000
Options vesting Shares | shares	97,165
Exercised Shares | shares	(182,853)
Forfeited/Cancelled Shares | shares	0
Outstanding ending balance Shares | shares	3,246,057
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 1.50
Granted Weighted Average Exercise Price | $ / shares	2.13
Options vesting Weighted Average Exercise Price | $ / shares	2.22
Exercised Weighted Average Exercise Price | $ / shares	1.38
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	0
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 1.58
Unvested Options [Member]
Outstanding beginning balance Shares | shares	245,835
Granted Shares | shares	189,708
Options vesting Shares | shares	97,165
Exercised Shares | shares	0
Forfeited/Cancelled Shares | shares	(20,417)
Outstanding ending balance Shares | shares	317,961
Outstanding beginning balance Weighted Average Exercise Price | $ / shares	$ 2.34
Granted Weighted Average Exercise Price | $ / shares	2.42
Options vesting Weighted Average Exercise Price | $ / shares	2.22
Exercised Weighted Average Exercise Price | $ / shares	0
Forfeited/Cancelled Weighted Average Exercise Price | $ / shares	1.92
Outstanding ending balance Weighted Average Exercise Price | $ / shares	$ 2.44

Stockholders' Equity - Estimate

Stockholders' Equity - Estimate the fair values (Details)	6 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Expected dividend yield	0.00%	0.00%
Expected volatility		64.00%
Minimum [Member]
Risk-free interest rate	0.37%	1.61%
Expected life (in years)	5 years	5 years
Expected volatility	60.00%	64.00%
Maximum [Member]
Risk-free interest rate	0.51%	1.69%
Expected life (in years)	6 years	6 years
Expected volatility	63.00%

Stockholders' Equity - Stock op

Stockholders' Equity - Stock options outstanding and exercisable (Details)	6 Months Ended
	Dec. 31, 2020$ / sharesshares
Options Outstanding	3,564,018
Options Exercisable	3,246,057
Range One [Member]
Option Exercise Price | $ / shares	$ 0.59
Options Outstanding	8,150
Remaining Contractual Life (in years)	1 year 6 months
Options Exercisable	8,150
Range Two [Member]
Option Exercise Price | $ / shares	$ 0.60
Options Outstanding	5,000
Remaining Contractual Life (in years)	1 year 6 months
Options Exercisable	5,000
Range Three [Member]
Option Exercise Price | $ / shares	$ 0.65
Options Outstanding	6,150
Remaining Contractual Life (in years)	1 year 6 months
Options Exercisable	6,150
Range Four [Member]
Option Exercise Price | $ / shares	$ 0.70
Options Outstanding	225,000
Remaining Contractual Life (in years)	4 years 11 months 5 days
Options Exercisable	225,000
Range Five [Member]
Option Exercise Price | $ / shares	$ 0.77
Options Outstanding	49,500
Remaining Contractual Life (in years)	2 years 6 months 29 days
Options Exercisable	49,500
Range Six [Member]
Option Exercise Price | $ / shares	$ 0.80
Options Outstanding	16,000
Remaining Contractual Life (in years)	4 years 7 months 21 days
Options Exercisable	16,000
Range Seven [Member]
Option Exercise Price | $ / shares	$ 0.90
Options Outstanding	25,667
Remaining Contractual Life (in years)	3 years 3 months 22 days
Options Exercisable	25,667
Range Eight [Member]
Option Exercise Price | $ / shares	$ 0.97
Options Outstanding	6,000
Remaining Contractual Life (in years)	1 year 6 months
Options Exercisable	6,000
Range Nine [Member]
Option Exercise Price | $ / shares	$ 1
Options Outstanding	28,249
Remaining Contractual Life (in years)	2 years 11 months 5 days
Options Exercisable	28,249
Range Ten [Member]
Option Exercise Price | $ / shares	$ 1.02
Options Outstanding	2,000
Remaining Contractual Life (in years)	1 year 6 months
Options Exercisable	2,000
Range Eleven [Member]
Option Exercise Price | $ / shares	$ 1.05
Options Outstanding	400,529
Remaining Contractual Life (in years)	5 years 7 months 2 days
Options Exercisable	400,529
Range Twelve [Member]
Option Exercise Price | $ / shares	$ 1.07
Options Outstanding	33,898
Remaining Contractual Life (in years)	1 year 9 months 15 days
Options Exercisable	33,898
Range Thirteen [Member]
Option Exercise Price | $ / shares	$ 1.09
Options Outstanding	121,250
Remaining Contractual Life (in years)	4 years 10 months 28 days
Options Exercisable	121,250
Range Fourteen [Member]
Option Exercise Price | $ / shares	$ 1.10
Options Outstanding	105,000
Remaining Contractual Life (in years)	4 years 6 months
Options Exercisable	105,000
Range Fifteen [Member]
Option Exercise Price | $ / shares	$ 1.15
Options Outstanding	193,400
Remaining Contractual Life (in years)	3 years 9 months 11 days
Options Exercisable	193,400
Range Sixteen [Member]
Option Exercise Price | $ / shares	$ 1.20
Options Outstanding	349,000
Remaining Contractual Life (in years)	6 years 7 months 13 days
Options Exercisable	349,000
Range Seventeen [Member]
Option Exercise Price | $ / shares	$ 1.25
Options Outstanding	32,000
Remaining Contractual Life (in years)	2 years 1 month 13 days
Options Exercisable	32,000
Range Eighteen [Member]
Option Exercise Price | $ / shares	$ 1.30
Options Outstanding	243,000
Remaining Contractual Life (in years)	1 year 2 months 5 days
Options Exercisable	243,000
Range Nineteen [Member]
Option Exercise Price | $ / shares	$ 1.50
Options Outstanding	195,000
Remaining Contractual Life (in years)	1 year 10 months 17 days
Options Exercisable	195,000
Range Twenty [Member]
Option Exercise Price | $ / shares	$ 1.59
Options Outstanding	25,000
Remaining Contractual Life (in years)	7 years 4 months 10 days
Options Exercisable	22,915
Range Twenty One [Member]
Option Exercise Price | $ / shares	$ 1.80
Options Outstanding	94,050
Remaining Contractual Life (in years)	2 years 7 months 17 days
Options Exercisable	94,050
Range Twenty Two [Member]
Option Exercise Price | $ / shares	$ 1.85
Options Outstanding	17,800
Remaining Contractual Life (in years)	2 years 3 months 15 days
Options Exercisable	17,800
Range Twenty Three [Member]
Option Exercise Price | $ / shares	$ 1.95
Options Outstanding	200,000
Remaining Contractual Life (in years)	7 years 6 months 4 days
Options Exercisable	166,666
Range Twenty Four [Member]
Option Exercise Price | $ / shares	$ 2.13
Options Outstanding	266,708
Remaining Contractual Life (in years)	9 years 10 months 17 days
Options Exercisable	250,000
Range Twenty Five [Member]
Option Exercise Price | $ / shares	$ 2.40
Options Outstanding	398,667
Remaining Contractual Life (in years)	7 years 10 months 13 days
Options Exercisable	359,833
Range Twenty Six [Member]
Option Exercise Price | $ / shares	$ 2.45
Options Outstanding	173,000
Remaining Contractual Life (in years)	9 years 7 months 2 days
Range Twenty Seven [Member]
Option Exercise Price | $ / shares	$ 2.49
Options Outstanding	50,000
Remaining Contractual Life (in years)	8 years 8 months 27 days
Options Exercisable	25,000
Range Twenty Eight [Member]
Option Exercise Price | $ / shares	$ 2.50
Options Outstanding	20,000
Remaining Contractual Life (in years)	8 years 4 months 17 days
Options Exercisable	11,667
Range Twenty Nine [Member]
Option Exercise Price | $ / shares	$ 2.99
Options Outstanding	8,000
Remaining Contractual Life (in years)	9 years 4 months 13 days
Range Thirty [Member]
Option Exercise Price | $ / shares	$ 3.13
Options Outstanding	258,000
Remaining Contractual Life (in years)	8 years 10 months 13 days
Options Exercisable	253,333
Range Thirty One [Member]
Option Exercise Price | $ / shares	$ 3.50
Options Outstanding	8,000
Remaining Contractual Life (in years)	9 years 1 month 13 days

Stockholders' Equity - Warrant

Stockholders' Equity - Warrant activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Non-vested, Ending balance	320,000
Exercisable	320,000
Warrant
Non-vested, Beginning balance	385,000
Granted	0
Exercised	(65,000)
Expired/Cancelled	0
Non-vested, Ending balance	320,000	385,000
Exercisable	320,000	385,000
Outstanding, Beginning balance Weighted Average Exercise Price	$ 1.24
Granted Weighted Average Exercise Price	0
Exercised Weighted Average Exercise Price	1.25
Expired/Cancelled Weighted Average Expired Price	0
Outstanding, Ending Balance Weighted Average Exercise Price	1.24	$ 1.24
Exercisable, Weighted Average Exercise Price	$ 1.24	$ 1.24

Stockholders' Equity - Warrants

Stockholders' Equity - Warrants outstanding and exercisable (Details)	6 Months Ended
	Dec. 31, 2020$ / sharesshares
Warrants Outstanding	320,000
Warrants Exercisable	320,000
Range One [Member]
Warrant Exercise Price | $ / shares	$ 1.19
Warrants Outstanding	50,000
Warrants Outstanding Remaining Contractual Life (in years)	11 months 19 days
Warrants Exercisable	50,000
Range Two [Member]
Warrant Exercise Price | $ / shares	$ 1.25
Warrants Outstanding	270,000
Warrants Outstanding Remaining Contractual Life (in years)	5 months 23 days
Warrants Exercisable	270,000

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted common stock activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2020	Jun. 30, 2020
Non-vested, Ending balance	320,000
Restricted Stock [Member]
Non-vested, Beginning balance	191,855
Granted Number of shares	143,474
Vested, Number of shares	(84,776)
Forfeited, Number of shares	0	(188,203)
Non-vested, Ending balance	250,553	191,855
Non-vested, Beginning balance	$ 394,297
Granted, Fair Value	344,000
Vested, Fair Value	(186,954)
Forfeited, Fair Value	0	$ 214,324
Non-vested, Ending balance	$ 551,343	$ 394,297
Non-vested, Beginning Balance Weighted Average Grant Date Fair Value	$ 2.51
Granted Weighted Average Grant Date Fair Value	2.40
Vested Weighted Average Grant Date Fair Value	2.29
Forfeited Weighted Average Grant Date Fair Value	0
Non-vested, Ending Balance Weighted Average Grant Date Fair Value	$ 2.52	$ 2.51

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	3 Months Ended				6 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2020	Feb. 11, 2020	Nov. 12, 2019	Nov. 21, 2017	Nov. 10, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					5 years 11 months 1 day
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term					5 years 8 months 19 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 2,697,071				$ 2,697,071
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 2,687,396				$ 2,687,396
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	320,000				320,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 93,790	$ 93,164	$ 85,640	$ 84,474
Stock Repurchase Program, Authorized Amount								$ 400,000
Stock Repurchased During Period, Value	68,879	58,395	127,499	71,875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					439,708
Fair value of vested stock options	342,158	$ 77,627	$ 437,992	$ 58,198	$ 419,785
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 392,185				392,185
Proceeds from Stock Options Exercised					14,100	$ 0
Proceeds from the exercise of warrants					$ 81,251	$ 0
exercise price	$ 1.25				$ 1.25
Warrants Exercised Shares					65,000
The Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period					1 year
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					10 years
2007 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0				0
2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,059,664				1,059,664					1,874,513
Common Stock
Stock Issued During Period, Shares, Restricted Stock Award, Gross	23,474	120,000	13,978	70,000
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 23	$ 120	$ 14	$ 70
Stock Repurchased During Period, Shares	31,167	25,500	42,500	28,750	56,667
Stock Repurchased During Period, Value	$ 31	$ 25	$ 42	$ 28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					81,938
Fair value of vested stock options	0	$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Other Share Increase (Decrease)					182,853
Proceeds from Stock Options Exercised					$ 14,000
Warrant
Intrinsic value of warrant	$ 348,600				348,600
Employee [Member]
Stock Repurchased During Period, Value					$ 127,274
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					439,708
Stock Granted, Value, Share-based Compensation, Gross					$ 522,954
Stock Repurchased Average Price Per Share					$ 2.25
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period					3 years
Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period					1 year
Stock or Unit Option Plan Expense							$ 1,785,857
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	250,553				250,553		191,855
Stock Issued During Period, Shares, Restricted Stock Award, Gross					143,474		2,277,366
Stock Issued During Period, Value, Restricted Stock Award, Gross					$ 344,000		$ 2,709,318
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value							$ 1,871,187
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period					0		188,203
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Fair Value					$ 0		$ 214,324
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value	$ 551,343				551,343		$ 394,297
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Fair Value					186,954
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants In Period, Fair Value					$ 344,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					143,474
Restricted Stock [Member] | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Fair Value					$ 186,954
Unvested Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					189,708
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant											5,000,000
Minimum [Member] | 2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant									2,374,513
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant											7,000,000
Share Price								$ 4
Stock Repurchased Average Price Per Share					$ 2.40
Maximum [Member] | 2017 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant									3,374,513

Subsequent Events (Details)

Subsequent Events (Details) - shares	Jan. 14, 2021	Dec. 31, 2020
Common stock issued upon exercise of stock options		182,853
Subsequent Event [Member]
Common stock issued upon exercise of stock options	11,671
Shares of common stock issued	26,667